generic glp-1 FDA Approves First Weight Loss Drug FDA approves 1st generic GLP-1

Sales of antiobesity drugs hit $1.1 billion in the second quarter of 2023.

KFFs latest Health Tracking Poll examines the publics views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes

Free weight loss consultations available.

We aim to evaluate if this reduction leads to increased gastric food retention, raising the risk of aspiration

These Gluten-free, non-GMO, GLP-1 supplement gummies are formulated with inulin fiber to support digestive comfort and clean daily supplementation

Purpose of Review To discuss current literature and provide practical recommendations for the safe and effective use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in people with inflammatory bowel disease (IBD) and type 2 diabetes (T2D) and/or obesity